The American College of Cardiology (ACC), the American Heart Association and nine other leading medical associations, today issued an updated guideline for the management of dyslipidemia-abnormal ...
WASHINGTON and DALLAS, March 13, 2026 /PRNewswire/ -- The American College of Cardiology (ACC), the American Heart Association and nine other leading medical associations, today issued an updated ...
The ACC and AHA released updated guidelines for the management of dyslipidemia to reduce risk for atherosclerotic cardiovascular disease.
Inclisiran, an siRNA therapy, significantly reduces LDL-C by 28.5% in adolescents with heterozygous familial hypercholesterolemia (HeFH).
Lipid-lowering therapy can be considered with a 10-year PREVENT-ASCVD risk estimate of 3% to <5% (borderline) and should be considered for those at 5% to <10% (intermediate) 10-year risk. For ...
Mama Loves to Eat on MSN
Top 3 natural foods that work like statins
Heart disease remains the world's leading cause of death, and elevated LDL cholesterol is one of its biggest drivers. Cardiovascular disease remains the leading cause of death worldwide, with elevated ...
In a traditional observational analysis, associations of LDL-C with incident chronic kidney disease (CKD), atherosclerotic cardiovascular disease (ASCVD), and all-cause mortality were U-shaped or ...
TORONTO, March 5, 2026 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and ...
Findings showed the trial met the primary endpoint, with enlicitide demonstrating a statistically significantly meaningful reduction in LDL-C compared with placebo. Topline data were announced from a ...
Compared with placebo, obicetrapib lowered LDL-C by 33% at day 84 (P .0001). Topline results were announced from a phase 3 trial evaluating obicetrapib, an investigational low dose cholesterol ester ...
In patients with cardiovascular disease or who are at high risk for CVD, lerodalcibep significantly decreases LDL-C. Lerodalcibep significantly decreases low-density lipoprotein cholesterol (LDL-C) in ...
In another study of dyslipidemic patients not treated with hypolipidemic drugs (baseline examination), a very good correlation between LDL-C and apoB (r = 0.903; p < 0.001) was found. [66] In spite of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results